...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin
【24h】

Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin

机译:脯氨酰4-羟化酶2通过Carabin的羟基化促进B细胞淋巴瘤进展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

B-cell lymphomas are heterogeneous blood disorders with limited therapeutic options, largely because of their propensity to relapse and become refractory to treatments. Carabin, a key suppressor of B-cell receptor signaling and proliferation, is inactivated in B-cell lymphoma by unknown mechanisms. Here, we identify prolyl 4-hydroxylase 2 (P4HA2) as a specific proline hydroxylase of Carabin. Carabin hydroxylation leads to its proteasomal degradation, thereby activating the Ras/extracellular signal-regulated kinase pathway and increasing B-cell lymphoma proliferation. P4HA2 is undetectable in normal B cells but upregulated in the diffuse large B-cell lymphoma (DLBCL), driving Carabin inactivation and lymphoma proliferation. Our results indicate that P4HA2 is a potential prognosis marker for DLBCL and a promising pharmacological target for developing treatment of molecularly stratified B-cell lymphomas.
机译:B细胞淋巴瘤是具有有限的治疗性选项的异质血液障碍,主要是因为它们的复发倾向并成为治疗难治性。 Carabin是B细胞受体信号传导和增殖的关键抑制器,通过未知机制在B细胞淋巴瘤中灭活。 这里,我们将脯氨酰4-羟化酶2(P4HA2)鉴定为卡宾蛋白的特异性脯氨酸羟化酶。 CARABIN羟基化导致其蛋白酶体降解,从而激活RAS /细胞外信号调节的激酶途径和增加B细胞淋巴瘤增殖。 P4HA2在正常B细胞中不可检测,但在弥漫性大B细胞淋巴瘤(DLBCL)中升高,驱动Carabin失活和淋巴瘤增殖。 我们的结果表明,P4HA2是DLBCL的潜在预后标志物和用于显影分子分层B细胞淋巴瘤的治疗的有希望的药理学靶标。

著录项

  • 来源
  • 作者单位

    Fudan Univ Shanghai Med Coll Dept Biochem &

    Mol Biol Key Lab Metab &

    Mol Med Minist Educ;

    Fudan Univ Dept Pathol Shanghai Canc Ctr Shanghai Peoples R China;

    Fudan Univ Shanghai Med Coll Dept Biochem &

    Mol Biol Key Lab Metab &

    Mol Med Minist Educ;

    Fudan Univ Shanghai Med Coll Dept Biochem &

    Mol Biol Key Lab Metab &

    Mol Med Minist Educ;

    Fudan Univ Dept Pathol Shanghai Canc Ctr Shanghai Peoples R China;

    Fudan Univ Shanghai Med Coll Dept Biochem &

    Mol Biol Key Lab Metab &

    Mol Med Minist Educ;

    Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Drug Discovery &

    Design Ctr;

    Shanghai Jiao Tong Univ Sch Med Dept Immunol &

    Microbiol Shanghai Inst Immunol Shanghai;

    Fudan Univ Dept Hematol Shanghai Peoples R China;

    Fudan Univ Shanghai Med Coll Dept Biochem &

    Mol Biol Key Lab Metab &

    Mol Med Minist Educ;

    Fudan Univ Shanghai Med Coll Dept Biochem &

    Mol Biol Key Lab Metab &

    Mol Med Minist Educ;

    Fudan Univ Sch Life Sci Shanghai Peoples R China;

    Univ Calif San Francisco Cardiovasc Res Inst San Francisco CA 94143 USA;

    Fudan Univ Dept Hematol Shanghai Peoples R China;

    Shanghai Jiao Tong Univ Sch Med Dept Immunol &

    Microbiol Shanghai Inst Immunol Shanghai;

    Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Drug Discovery &

    Design Ctr;

    Univ Calif San Francisco Cardiovasc Res Inst San Francisco CA 94143 USA;

    Johns Hopkins Univ Sch Med Dept Pharmacol &

    Mol Sci Baltimore MD 21205 USA;

    Fudan Univ Shanghai Med Coll Dept Biochem &

    Mol Biol Key Lab Metab &

    Mol Med Minist Educ;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 血液及淋巴系疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号